Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC

被引：3

作者：

Peng, Ling ^{[1
]}

Xiao, Kui ^{[2
]}

Cui, Jian ^{[3
]}

Ye, Xiang-Hua ^{[4
]}

Zhang, Yong-Chang ^{[5
]}

Mao, Li ^{[6
]}

Selvaggi, Giovanni ^{[7
]}

Yen, Jennifer ^{[8
]}

Stebbing, Justin ^{[9
]}

机构：

[1] Zhejiang Prov Peoples Hosp, Dept Pulm & Crit Care Med, 158 Shangtang Rd, Hangzhou, Zhejiang, Peoples R China

[2] Cent South Univ, Xiangya Hosp 2, Dept Pulm & Crit Care Med, Changsha, Hunan, Peoples R China

[3] Shanghai BioGenius Bioinformat Inst, Shanghai, Peoples R China

[4] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Radiotherapy, Hangzhou, Zhejiang, Peoples R China

[5] Hunan Canc Hosp, Affiliated Canc Hosp, Dept Med Oncol, Lung Canc & Gastrointestinal Unit,Xiangya Sch Med, Changsha, Hunan, Peoples R China

[6] Betta Pharmaceut, Hangzhou, Peoples R China

[7] X Covery Holdings, Palm Beach Gardens, FL USA

[8] Guardant Hlth Inc, Redwood City, CA USA

[9] Imperial Coll London, Dept Surg & Canc, Div Canc, London, England

来源：

ONCOTARGETS AND THERAPY | 2021年 / 14卷

关键词：

ensartinib; alectinib; hyperbilirubinemia; NSCLC; ALK; CELL LUNG-CANCER; KINASE INHIBITORS; CRIZOTINIB; EFFICACY; SAFETY;

D O I：

10.2147/OTT.S310756

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Background: Alectinib is approved for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring ALK rearrangements. Although generally well tolerated, alectinib can cause serious or life-threatening side effects. Case Presentation: Here, we report a case of a patient with NSCLC with an EML4-ALK fusion and was treated with alectinib but who developed grade 4 hyperbilirubinemia after five months on therapy. Alectinib was discontinued, and an artificial liver support system (ALSS) was used with an impressive decline in bilirubin levels. After two months drug-free, the patient experienced disease progression. Ensartinib was initiated as second-line treatment with a best response of stable disease after three months of therapy with no evidence of hyperbilirubinemia. Conclusion: This is the first report of ensartinib treatment after alectinib-induced hyperbilirubinemia which was successfully relieved by ALSS treatment and targeted drug cessation.

引用

页码：3409 / 3415

页数：7

共 23 条

[1] Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury [J].

Ali, Serat-E ;

Waddington, James C. ;

Park, B. Kevin ;

Meng, Xiaoli .

CHEMICAL RESEARCH IN TOXICOLOGY, 2020, 33 (01) :61-76

[2] Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis [J].

Breadner, Daniel ;

Blanchette, Phillip ;

Shanmuganathan, Sumugan ;

Boldt, Ronald Gabriel ;

Raphael, Jacques .

LUNG CANCER, 2020, 144 :57-63

[3]

Charville Gregory W, 2018, Case Reports Hepatol, V2018, P3413592, DOI 10.1155/2018/3413592

[4] Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems [J].

Gonzalez, Humberto C. ;

Jafri, Syed-Mohammed ;

Gordon, Stuart C. .

CLINICS IN LIVER DISEASE, 2017, 21 (01) :163-+

[5]

Grove J, 2014, EXPERT OPIN DRUG MET, V11, P1

[6] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial [J].

Hida, Toyoaki ;

Nokihara, Hiroshi ;

Kondo, Masashi ;

Kim, Young Hak ;

Azuma, Koichi ;

Seto, Takashi ;

Takiguchi, Yuichi ;

Nishio, Makoto ;

Yoshioka, Hiroshige ;

Imamura, Fumio ;

Hotta, Katsuyuki ;

Watanabe, Satoshi ;

Goto, Koichi ;

Satouchi, Miyako ;

Kozuki, Toshiyuki ;

Shukuya, Takehito ;

Nakagawa, Kazuhiko ;

Mitsudomi, Tetsuya ;

Yamamoto, Nobuyuki ;

Asakawa, Takashi ;

Asabe, Ryoichi ;

Tanaka, Tomohiro ;

Tamura, Tomohide .

LANCET, 2017, 390 (10089) :29-39

[7] Safety issues with the ALK inhibitors in the in the treatment of NSCLC: A systematic review [J].

Kassem, Loay ;

Shohdy, Kyrillus S. ;

Lasheen, Shaimaa ;

Abdel-Rahman, Omar ;

Ali, Ahmad ;

Abdel-Malek, Raafat R. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 134 :56-64

[8] FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements [J].

Kazandjian, Dickran ;

Blumenthal, Gideon M. ;

Chen, Huan-Yu ;

He, Kun ;

Patel, Mona ;

Justice, Robert ;

Keegan, Patricia ;

Pazdur, Richard .

ONCOLOGIST, 2014, 19 (10) :E5-E11

[9]

Liu B, 2018, METAANALYSIS, V9, P9480, DOI [10.18632/ oncotarget.23840, DOI 10.18632/ONCOTARGET.23840]

[10] Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines [J].

Mingard, Cecile ;

Paech, Franziska ;

Bouitbir, Jamal ;

Krahenbuhl, Stephan .

JOURNAL OF APPLIED TOXICOLOGY, 2018, 38 (03) :418-431

← 1 2 3 →